Management Or Ownership Change
Expected: Feb 2026LOW confidence
What: Board Appointment: Dr. Swati Patankar
Unichem Laboratories Ltd: Is It a Deep Value Opportunity?
AverageAccelerating
As of , Unichem Laboratories Ltd (Pharma - Others) has a deep value score of 47/100 (rated Average). Earnings are accelerating. 1Y return vs Nifty 500: -36%.
Unichem Laboratories Ltd Key Facts
- PE Ratio
- 25.8x
- Market Cap
- ₹2,716 Cr
- Value Score
- 47/100
- Margin of Safety
- 76%
- PAT Growth YoY
- +355%
- Revenue Growth YoY
- -2%
- OPM
- 9.0%
PE: Cycle BottomStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💰Trading 76% below estimated fair value — significant discount
Earnings Acceleration Triggers
1. Management Or Ownership Change
Feb 2026LOW
Key Risks
1. Settlement of €19
HIGH2. USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedura
MEDIUMSector-Specific Signals
FDA Inspection Status5 Observations
Standalone Revenue Growth₹314.90 Cr-29.69%
Operating Margin (Excl. Other Income)8.59%-746 bps
Key Numbers
PAT Growth YoY
+355%
Stable
Revenue YoY
-2%
Inflection Down
Operating Margin
9.0%
-700 bps YoY
PE Ratio
25.8
PEG Ratio
0.17
Current Price
₹386
3Y PAT CAGR
+61%
Market Cap
2.7K Cr
Valuation
Significantly UndervaluedWhy Are Unichem Laboratories Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 18, 2026
What Are the Key Risks for Unichem Laboratories Ltd?
Earnings deceleration risks from management commentary
Settlement of €19
HIGHTrigger: Settlement of €19.49 million (₹175 Cr) fine with European Commission regarding Perindopril patent dispute.
Impact: PAT impact: ₹175 Cr
Management view: Paid €16.75 million in Oct 2025 to conclude the matter.
Monitor: litigation
USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedura
MEDIUMTrigger: USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedural observations.
Management view: Stated observations are procedural and not data integrity related; response within 15 days.
Monitor: regulatory
What Did Unichem Laboratories Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹521.17 Cr
YoY -2.24%QoQ -9.98%
Revenue hit the lowest quarterly level in FY26, underperforming the broader stable pharmaceutical sector.
EBITDA
₹44.78 Cr
YoY -47.65%Margin 8.59%
Core operating profitability nearly halved YoY as margins compressed by 746 basis points.
PAT
₹264.29 Cr
YoY +356.85%QoQ +2322.79%
Headline PAT was heavily inflated by a one-time exceptional gain of ₹275.52 Cr from land and building sales.
Other Highlights
• Exceptional gain of ₹275.52 Cr from sale of land and buildings drove PAT surge.
• Standalone revenue plummeted 29.69% YoY to ₹314.90 Cr.
• Operating margin (excl. OI) compressed 746 bps YoY to 8.59%.
What Sector Metrics Matter for Unichem Laboratories Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
FDA Inspection Status
5 Observations
Why: USFDA inspection at Kolhapur API site in Feb 2026 concluded with procedural observations.
Standalone Revenue Growth
₹314.90 Cr
YoY -29.69%
Why: Sharp decline suggests operational challenges or slowdown in key business segments.
Operating Margin (Excl. Other Income)
8.59%
YoY -746 bpsQoQ -284 bps
Why: Persistent pressure on core business operations and lack of pricing power.
What Is Unichem Laboratories Ltd's Management Guidance?
Forward-looking targets from management
Management Tone: CAUTIOUS
How Fast Is Unichem Laboratories Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -2% | +18% | Inflection Down |
| PAT (Net Profit) | +355% | +61% | Stable |
| OPM | 9.0% | -700 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Frequently Asked Questions: Unichem Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Unichem Laboratories Ltd's deep value score?
Unichem Laboratories Ltd has a deep value score of 47/100 (rated Average). This score is calculated from three components
- Earnings Score: 33/40 — measures PAT growth momentum across quarters
- Underperformance Score: 20/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
- Quality Score: 19/25 — operational quality (margins, revenue growth, valuation)
Is Unichem Laboratories Ltd fundamentally improving?
Unichem Laboratories Ltd's quarterly profit (PAT) growth trajectory
- Latest Quarter PAT Growth (QoQ): +500%
- Previous Quarter PAT Growth (QoQ): -14%
- 2 Quarters Ago PAT Growth (QoQ): -120%
- PAT Acceleration: +309.9pp (profits are accelerating)
- 1 consecutive quarters of positive PAT growth
Why is Unichem Laboratories Ltd underperforming despite good earnings?
Unichem Laboratories Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
- 1-Year Return vs Nifty 500: -36%
- 6-Month Return vs Nifty 500: -14%
- 3-Month Return vs Nifty 500: -1%
- Yet average quarterly PAT growth is +122% — earnings are improving
- The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.
What is the earnings momentum for Unichem Laboratories Ltd?
Unichem Laboratories Ltd's earnings momentum is Accelerating — profit growth is speeding up.
- PAT QoQ progression: -120% → -14% → +500% (2Q ago → 1Q ago → latest)
- Acceleration: +309.9pp
- PAT YoY Growth: +355%
Is Unichem Laboratories Ltd undervalued?
Unichem Laboratories Ltd's valuation metrics
- Price-to-Earnings (PE): 9.2x
- Price-to-Book (PB): 1.1x
- PEG Ratio: 0.2x
- Margin of Safety: +61% (appears undervalued)
What are the revenue and margin trends for Unichem Laboratories Ltd?
Unichem Laboratories Ltd's revenue and margin trends
- Latest Quarter Revenue Growth (QoQ): -10%
- Average Quarterly Revenue Growth: -3%
- Revenue Acceleration: +0.2pp
- Latest OPM Change: -2.8pp (margins contracting)
- Average OPM Change: -1.9pp
- Revenue YoY: -2%
What is Unichem Laboratories Ltd's trailing twelve month (TTM) performance?
Unichem Laboratories Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹295 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +13.3% YoY
- TTM Operating Margin: 9.7%
What sector does Unichem Laboratories Ltd belong to?
Unichem Laboratories Ltd key facts
- Sector: Pharma - Others
- Market Cap: ₹2.7K Cr
- Rank in Pharma - Others: #1 by value score
- Overall rank among all deep value stocks: #5
Is Unichem Laboratories Ltd a good deep value opportunity to study?
Unichem Laboratories Ltd shows limited deep value signals currently — score is 47/100 (Average). Monitor for improvement.
- Value Score: 47/100 (Average)
- Earnings: Accelerating
- 1Y Underperformance: -36% vs Nifty 500
What is the bull and bear case for Unichem Laboratories Ltd?
Research Signals (Bull Case)
- Earnings accelerating — profit growth speeding up
- Appears undervalued based on fair value analysis
- Revenue growth also accelerating
Risk Factors (Bear Case)
- Significant underperformance (-36% vs Nifty 1Y)
- Margin pressure warning
- Operating margins contracting
How does the Pharma - Others sector look for deep value?
Pharma - Others deep value sector overview
- 1 deep value stocks in this sector
- Average value score: 47/100
- Avg PAT acceleration: +309.9pp
- Top pick: Unichem Laboratories Ltd
What is deep value investing?
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
How is the deep value score calculated?
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
What are the growth catalysts for Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 1 key growth catalyst identified from recent earnings analysis
- Management Or Ownership Change
What are the key risks in Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 2 key risks worth monitoring
- Settlement of €19
- USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedura
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.